Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMINO Study of faricimab versus aflibercept for macular edema due to CRVO or HRVO
MOH_2020-12-31_009627Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of faricimab in Vein occlusion (RVO), central retinal vein occlusion (CRVO), hemiretinal vein occlusion (HRVO) and 1 more (2 arms), sponsored by Roche. Primary endpoint: Change from baseline in best-corrected visual acuity at Week 24. Started Dec 2020; status: completed.
02
Drugs
faricimab
03
Conditions
Vein occlusion (RVO)central retinal vein occlusion (CRVO)hemiretinal vein occlusion (HRVO)macular edema
Beyond the preview
Go deeper on MOH_2020-12-31_009627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-31_009627.